

Faculty Affiliations and Disclosures

Chair/Planner

Prof. Dr. med. Stephan Stilgenbauer
Professor of Medicine and Medical Director
Head Early Clinical Trials Unit (ECTU), CCCU
Comprehensive Cancer Center Ulm
Head Division of CLL, Department of Internal Medicine III
Ulm University
Ulm, Germany

Prof. Dr. med. Stephan Stilgenbauer has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; Acerta Pharma; Amgen Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Incyte Corporation; Infinity Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC; and Sunesis Pharmaceuticals, Inc.

Grant/Research Support from AbbVie Inc.; Acerta Pharma; Amgen Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Incyte Corporation; Infinity Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC; and Sunesis Pharmaceuticals, Inc.

Speakers Bureau participant with AbbVie Inc.; Acerta Pharma; Amgen Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Incyte Corporation; Infinity Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC; and Sunesis Pharmaceuticals, Inc.

Other Financial or Material Support as independent contractor for AbbVie Inc.; Acerta Pharma; Amgen Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Incyte Corporation; Infinity Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC; and Sunesis Pharmaceuticals, Inc.

Presenter

Matthew S. Davids, MD, MMSc
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Matthew S. Davids, MD, MMSc, has a financial relationship or affiliation in the form of: Consultant or advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene Co., Ltd; Bristol Myers Squibb Company; Genentech; Genmab;

Janssen; Lilly; Merck; MingSight Pharmaceuticals; Secura Bio; Takeda; TG Therapeutics Inc.

Research funding from AbbVie; Ascentage Pharma; AstraZeneca; Genentech; Novartis; Secura Bio; TG Therapeutics, Inc.

Presenter

Dr. Lydia Scarfo, MD

Strategic Research Program on CLL

Universita Vita Salute San Raffaele and IRCCS Ospedale San Raffaele
Milano, Italy

Dr. Lydia Scarfo, MD, has a financial relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene, Inc.; Lilly; and Janssen.
Speakers Bureau participant with Octapharma.